(Reuters) - But the trial was too small to tell if Sprycel is superior, researchers told a meeting of cancer specialists. More tests are needed to show if Sprycel should be given first, keeping Gleevec as a back-up if the cancer, a type known as chronic myelogenous leukemia or CML, comes back.
"This is a hint that it might be as good or maybe a little bit better initially," said Dr. Mitchell Smith, of Fox Chase Cancer Center in Philadelphia, who was not involved with the study.
Read more at Reuters.com Government Filings News
"This is a hint that it might be as good or maybe a little bit better initially," said Dr. Mitchell Smith, of Fox Chase Cancer Center in Philadelphia, who was not involved with the study.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment